US University started a clinical trial of Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

The University of California, Irvine is commencing recruitment for the clinical trial of the Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma.

The conditions are Basal Cell Carcinoma, Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma.

A new clinical trial is recruiting patients in the following locations: United States.

The trial officially began on the January 13, 2021 and is planned to complete on December 31, 2023.

The purpose of this pilot study is to examine the treatment basal cell carcinoma (BCC) with laser technology under the guidance of optical coherence tomography imaging (OCT). The laser modality that researchers plan to use is the long-pulse Nd:YAG 1064nm laser, which is a non-ablative laser already shown to effectively treat BCC. Laser treatment of BCC has limited precedent in the literature, but the addition of OCT has the opportunity to enhance outcomes by better targeting the treatment and permitting more precise monitoring of clearance. The researchers propose to use OCT imaging to guide the laser treatment to achieve optimal efficacy with minimized side-effects.

The population that can be enrolled into this study includes:

• Ability to understand and carry out subject instructions or be represented by a legally authorized guardian or representative
• Ages 18 and older
• Seeks and is scheduled for treatment of a BCC previously confirmed with biopsy

Among the exclusion criteria are:

• Inability to understand and/or carry out instructions
• Patients with a BCC lesion that requires excision. This would include relatively large lesions (>2.5 cm diameter), lesions that penetrate deep into the skin beyond the depth of the OCT image capture, high risk lesions as defined by the American Academy of Dermatology as recurrent and sclerosing subtype BCC, or metastases.
• Patients with periocular BCCs which might expose the patient to risk of damage to eyes from the laser.
• BCCs on legs due to their tendency towards poor wound healing.
• Pregnancy.
• Patients unable to follow-up for the full 12 months.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04744935